• Mashup Score: 0

    Patients with juvenile idiopathic arthritis who undergo therapy with TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022. Check out the year’s top-performing stories detailing juvenile idiopathic arthritis from Healio below:

    Tweet Tweets with this article
    • ICYMI: Patients with juvenile idiopathic #arthritis who undergo therapy with #TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022. #MedTwitter #RheumTwitter https://t.co/9f1WzUiBwG

  • Mashup Score: 0

    Patients with juvenile idiopathic arthritis who undergo therapy with TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022. Check out the year’s top-performing stories detailing juvenile idiopathic arthritis from Healio below:

    Tweet Tweets with this article
    • Patients with juvenile idiopathic #arthritis who undergo therapy with #TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022. #MedTwitter #RheumTwitter https://t.co/9f1WzUiBwG

  • Mashup Score: 0

    The official source for NFL news, video highlights, fantasy football, game-day coverage, schedules, stats, scores and more.

    Tweet Tweets with this article
    • Ahead of tonight’s @NFL, #TNF, @AtlantaFalcons v. @Panthers match-up, the https://t.co/fDFZ243OVV injury report listed offensive lineman @tmoton72 as “questionable” after missing Week 9. While his elbow doesn’t appear to be the concern, https://t.co/QVpbksTtVf

  • Mashup Score: 0

    Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.

    Tweet Tweets with this article
    • ICYMI: “There have been several trials performed that have showed the superior efficacy of #JAK inhibitors [...], but only in a few studies were they were compared to another second-line therapy, and only a #TNF inhibitor,” @k_lauper said @Hopitaux_unige https://t.co/ue8rhysW91

  • Mashup Score: 0

    Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.

    Tweet Tweets with this article
    • ICYMI: “There have been several trials performed that have showed the superior efficacy of #JAK inhibitors [...], but only in a few studies were they were compared to another second-line therapy, and only a #TNF inhibitor,” @k_lauper said @Hopitaux_unige https://t.co/ue8rhysW91

  • Mashup Score: 2

    Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.

    Tweet Tweets with this article
    • Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of #TNF inhibitors in patients with rheumatoid #arthritis @k_lauper @Hopitaux_unige https://t.co/ue8rhysW91